Miller Value Partners (Bill Miller)
MILLER VALUE PARTNERS, LLC · SARASOTA, FL · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗Value Investor
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$461.3M2026 Q3
Positions53
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.55.5%
AUM History
Quarterly History · 40 Quarter
| Quarter | Filed | Holdings | Total Value | Turnover %Turnover = (value of positions opened + previous value of positions closed + |change in shares| × price for names held in both quarters) / the average portfolio value of the two quarters. Price moves do not count; a quarter with any trade is never 0%. | Top 10 |
|---|---|---|---|---|---|
| 2026 Q3 | 2026-11-16 | 53 | $461.3M | 26.8% | NBR, GTN, CRGY, SPUU, CNDT, CNXC, QUAD, BLMN, LNC, COTY |
| 2026 Q2 | 2026-08-14 | 56 | $423.1M | 28.2% | NBR, GTN, SPUU, BLMN, QUAD, LNC, CRGY, CNDT, BFH, UPS |
| 2026 Q1 | 2026-05-15 | 55 | $383.2M | 52.6% | NBR, CRGY, GTN, LNC, SPY, QUAD, BFH, TDAY, CNDT, UPS |
| 2025 Q4 | 2026-02-17 | 34 | $283.8M | 13.7% | NBR, LNC, GTN, TDAY, QUAD, BFH, FOSL, DCH, CNDT, JELD |
| 2025 Q3 | 2025-11-14 | 36 | $272.2M | 22.3% | NBR, LNC, GTN, QUAD, BFH, TDAY, CNDT, DCH, JELD, JXN |
| 2025 Q2 | 2025-08-14 | 33 | $235.7M | 16.6% | LNC, BFH, NBR, GTN, QUAD, TDAY, JXN, UGI, VZ, OMF |
| 2025 Q1 | 2025-05-15 | 34 | $219.4M | 26.1% | LNC, NBR, BFH, GTN, QUAD, JXN, UGI, VZ, TDAY, CTO |
| 2024 Q4 | 2025-02-14 | 33 | $234.2M | 33.6% | BFH, QUAD, NBR, LNC, T, TDAY, JXN, WAL, UNFI, GTN |
| 2024 Q3 | 2024-11-14 | 30 | $177.2M | 24.9% | BFH, LNC, JXN, T, WAL, NBR, QUAD, MSTR, GTN, TDAY |
| 2024 Q2 | 2024-08-13 | 29 | $156.6M | 20.2% | BFH, T, JXN, LNC, WAL, STLA, QUAD, CTO, CHRD, NBR |
| 2024 Q1 | 2024-05-07 | 30 | $156.4M | 51.7% | STLA, MICROSTRATEGY INC, T, JXN, BFH, WAL, OMF, QUAD, CTO, VTRS |
| 2023 Q4 | 2024-02-14 | 42 | $168.4M | 22.9% | STLA, WAL, UPRO, JXN, BFH, T, QUAD, OMF, BKE, VTRS |
| 2023 Q3 | 2023-11-14 | 46 | $159.1M | 33.4% | STLA, JXN, WAL, QUAD, T, UPRO, BFH, VTRS, CTO, OMF |
| 2023 Q2 | 2023-08-14 | 46 | $152.0M | 172.1% | UPRO, STLA, VTRS, OMF, CTO, CHICOS FAS INC, WAL, JXN, BKE, RILY |
| 2023 Q1 | 2023-05-15 | 90 | $1.60B | 18.8% | OMF, EXPE, AMZN, TMHC*, GOOGL, ET, META, MAT, DAL, BABA |
| 2022 Q4✎ amendment applied | 2023-02-14 | 79 | $1.55B | 28.4% | OVV, OMF, EXPE, TMHC*, MAT, ET, AMZN, DAL, GOOGL, BABA |
| 2022 Q3 | 2022-11-14 | 87 | $1.65B | 17.0% | OVV, AMZN, EXPE, TEVA, MAT, ET, GOOGL, OMF, TMHC*, BABA |
| 2022 Q2 | 2022-08-15 | 83 | $1.97B | 23.1% | BABA, OVV, MAT, DXC, OMF, AMZN, GOOGL, TEVA, TMHC*, EXPE |
| 2022 Q1 | 2022-05-16 | 89 | $3.11B | 14.7% | AMZN, OVV, NCLH, DXC, SPLKCHF, TEVA, GOOGL, TIVITY HEALTH INC, BABA, MAT |
| 2021 Q4 | 2022-02-14 | 94 | $3.65B | 21.1% | AMZN, DXC, FANG, META, ADT, GOOGL, TMHC*, TIVITY HEALTH INC, NCLH, MAT |
| 2021 Q3 | 2021-11-15 | 96 | $4.31B | 21.2% | AMZN, DXC, SPLKCHF, GOOGL, META, ADT, NCLH, TEVA, FANG, BABA |
| 2021 Q2 | 2021-08-16 | 100 | $4.20B | 19.4% | DXC, ADT, AMZN, BABA, OMF, SPLKCHF, FANG, FTCHQ, NCLH, META |
| 2021 Q1 | 2021-05-17 | 94 | $3.86B | 21.3% | DXC, OMF, FTCHQ, TEVA, AMZN, ADT, NCLH, VROOM INC, QUOTIENT TECHNOLOGY INC, BHC |
| 2020 Q4 | 2021-02-16 | 85 | $3.29B | 43.1% | FTCHQ, DXC, AMZN, DESKTOP METAL INC, SFIX, OMF, ADT, META, BABA, VROOM INC |
| 2020 Q3 | 2020-11-16 | 84 | $2.79B | 29.6% | FTCHQ, AMZN, ADT, BABA, DXC, META, TMHC*, OMF, CC, TEVA |
| 2020 Q2 | 2020-08-14 | 78 | $2.25B | 22.3% | FTCHQ, AMZN, ADT, TEVA, META, MED, GOOGL, FLEXION THERAPEUTICS INC, DXC, TMHC* |
| 2020 Q1 | 2020-05-15 | 73 | $1.55B | 48.4% | AMZN, TEVA, ADT, FTCHQ, BABA, META, GOOGL, LEN, ENDPUSD, UAL |
| 2019 Q4 | 2020-02-14 | 90 | $2.82B | 19.7% | ADT, BHC, AMZN, OMF, FLEXION THERAPEUTICS INC, MED, TEVA, RH, MU, BHF |
| 2019 Q3 | 2019-11-14 | 96 | $2.49B | 19.5% | RH, AMZN, ADT, OMF, BHC, BHF, GNW, LEN, JPM, NXPI |
| 2019 Q2 | 2019-08-14 | 95 | $2.63B | 21.5% | AMZN, BHC, RH, OMF, ADT, META, BHF, JPM, AVON PRODS INC, QUOTIENT TECHNOLOGY INC |
| 2019 Q1 | 2019-05-15 | 100 | $2.52B | 16.0% | AMZN, BHC, OMF, RH, BHF, AVON PRODS INC, GNW, MU, JPM, NXPI |
| 2018 Q4 | 2019-02-14 | 100 | $2.20B | 11.7% | AMZN, RH, GNW, BHC, OMF, JPM, UAL, DAL, ENDPUSD, CTLEUR |
| 2018 Q3 | 2018-11-14 | 108 | $3.10B | 39.9% | AMZN, ENDPUSD, RH, BHC, OMF, CTLEUR, MALLINCKRODT PUB LTD CO, META, ADT, UAL |
| 2018 Q2✎ amendment applied | 2018-08-14 | 109 | $2.68B | 15.5% | AMZN, RH, VALEANT PHARMACEUTICALS INTL, OMF, GNW, ENDPUSD, DAL, JPMORGAN CHASE & CO, LEN, UAL |
| 2018 Q1 | 2018-05-15 | 107 | $2.40B | 13.5% | AMZN, RH, OMF, VALEANT PHARMACEUTICALS INTL, DAL, JPMORGAN CHASE & CO, LEN, AAL, INTREXON CORP, UAL |
| 2017 Q4 | 2018-02-14 | 107 | $2.35B | 17.2% | VALEANT PHARMACEUTICALS INTL, AMZN, RH, OMF, DAL, LEN, AAL, JPMORGAN CHASE & CO, PHM, UAL |
| 2017 Q3 | 2017-11-14 | 106 | $2.33B | 14.5% | AMZN, RH, OMF, VALEANT PHARMACEUTICALS INTL, QUOTIENT TECHNOLOGY INC, DAL, MTG, AAL, PLATFORM SPECIALTY PRODS COR, JPMORGAN CHASE & CO |
| 2017 Q2 | 2017-08-14 | 110 | $2.47B | 11.2% | RH, VALEANT PHARMACEUTICALS INTL, AMZN, PLATFORM SPECIALTY PRODS COR, DAL, OMF, INTREXON CORP, W, AAL, LEN |
| 2017 Q1 | 2017-05-12 | 66 | $2.27B | 29.7% | RH, AMZN, PLATFORM SPECIALTY PRODS COR, OMF, LEN, DAL, UAL, GNW, AAL, JPMORGAN CHASE & CO |
| 2016 Q4 | 2017-02-14 | 57 | $2.28B | 22.2% | UAL, DAL, AAL, AMZN, MTG, BAC, JPMORGAN CHASE & CO, INTREXON CORP, OMF, PANDORA MEDIA INC |
Share counts are split-adjusted. Time held counts consecutive quarters ending with the latest filing; more than ten years shows as ">10 Years".
Related managers
Five closest superinvestors by Jaccard overlap of tickers held in the latest quarter (computed nightly).
| Manager | Overlap | Shared holdings |
|---|---|---|
| DME Capital Management (Greenlight, David Einhorn) | 5.4% | CROX, VTRS, DCH, REZI, ADIG |
| Light Street Capital Management | 2.7% | META, MELI |
| Glenview Capital Management | 2.6% | CART, META, VTRS, ABNB |
| GMO (Jeremy Grantham) | 2.6% | BMY, LNC, UPS, META, LYB, VZ, AMP, ACI |
| Davis Selected Advisers (Chris Davis) | 2.5% | META, VTRS, LYB, PINS |
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.